Navigation Links
CuraGen Reports Third Quarter 2007 Financial Results
Date:10/25/2007

BRANFORD, Conn., Oct. 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today reported its financial results for the third quarter of 2007. For the quarter ended September 30, 2007, CuraGen reported a net loss of $9.9 million, or $0.18 per share, compared to a consolidated net loss of $15.9 million, or $0.29 per share, for the same period in 2006.

As of September 30, 2007, CuraGen had cash and investments of $153.6 million. Of the available cash and investments, $14.4 million is classified as restricted cash until August 2008 and relates to funds held in escrow following the sale of CuraGen's ownership in 454 Life Sciences. At the end of the third quarter, CuraGen had outstanding convertible debt of $109.4 million, compared to $176.2 million at December 31, 2006.

During the third quarter, $9.7 million of cash and investments was used to support continuing operations, which excluded payments of approximately $1 million for severance and related benefits. Cash and investments used during the quarter was offset by proceeds of $2.8 million primarily from the sale of assets disposed of in connection with the previously announced closure of the BPS facility and $6.3 million from the sale of long-term marketable securities.

"We believe that CuraGen's cash position provides us with the resources and flexibility to advance our products through value-creating milestones and potentially bring them to market," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen. "We continue to focus our clinical development efforts on belinostat, our HDAC inhibitor that is currently in a broad Phase II program exploring multiple indications, and on CR011-vcMMAE, which is treating patients with metastatic melanoma in a Phase I dose escalation trial. An update on these programs will be provided on Thursday, October 25th after clinical trial results are presented at the AACR-NCI-EORTC International Conference. These results, along with additional belinostat data being reported in December at the 2007 ASH Annual Meeting, will allow us to shape our plans to move our first product into Phase III in 2008."

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company's future cash and investment positions, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CRGN-F

CuraGen Contact:

Glenn Schulman, Pharm.D.

Director of Investor Relations

gschulman@curagen.com

(888) 436-6642

CURAGEN CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

(unaudited) (unaudited)

Collaboration revenue $22 - $66 $2,284

Operating expenses:

Research and development 8,074 10,692 30,480 33,139

General and administrative 2,568 3,556 9,631 10,287

Restructuring and other charges 1,058 - 8,537 -

Total operating expenses 11,700 14,248 48,648 43,426

Loss from operations (11,678) (14,248) (48,582) (41,142)

Interest income 1,861 1,742 4,060 5,452

Interest expense (1,273) (2,334) (4,172) (7,019)

Gain on extinguishment of debt 169 - 169 -

Gain on sale of long-term

marketable securities 973 - 973 -

Loss from continuing operations

before income tax benefit (9,948) (14,840) (47,552) (42,709)

Income tax benefit 50 52 160 161

Loss from continuing operations (9,898) (14,788) (47,392) (42,548)

Discontinued operations:

Loss from discontinued

operations - (1,092) (2,991) (1,495)

Gain on sale of subsidiary - - 78,352 -

Net (loss) income from

discontinued operations - (1,092) 75,361 (1,495)

Net (loss) income ($9,898) ($15,880) $27,969 ($44,043)

Basic and diluted net loss per

share from continuing operations ($0.18) ($0.27) ($0.85) ($0.77)

Basic and diluted net (loss)

income per share from

discontinued operations - (0.02) 1.35 (0.03)

Basic and diluted net (loss)

income per share ($0.18) ($0.29) $0.50 ($0.80)

Weighted average number of shares

used in computing basic and

diluted net (loss) income per

share 55,965 54,932 55,699 54,784

SELECTED BALANCE SHEET INFORMATION

September 30, December 31,

2007 2006

(unaudited)

Cash and investments (excluding

restricted cash) $139,217 $164,393

Restricted cash 14,366 -

Working capital 147,630 95,985

Total assets 158,497 227,294

Convertible subordinated debentures 109,391 176,228

Total long-term liabilities 110,499 111,174

Accumulated deficit 485,003 512,972

Stockholders' equity 39,678 8,767


'/>"/>
SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook ... Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the ... is their favorite way to cook a hot dog, far outpacing other cooking methods ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia ... to its specialty academic programs. , Answering to the increasing demand for curricular ... in health law, and environmental and land use law. ,  , “The demand ...
(Date:5/26/2016)... ... 2016 , ... On Memorial Day, Hope For Heroes and USA ... battle for the country. The nonprofit Hope For Heroes partnered with the leading ... independence for disabled military veterans, as well as police, firemen, and EMS professionals across ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology: